GAITHERSBURG, Md., Jan. 15 /PRNewswire-FirstCall/ -- MedImmune, Inc.'s
(Nasdaq: MEDI) fourth quarter and year end financial results for 2003 will be
released on Thursday, January 29, 2004 before the opening of the U.S.
financial markets. The company will also host a conference call and live
audio webcast at 8:00 a.m. Eastern time following the announcement. During
the conference call, MedImmune's management will discuss the financial results
and other business.
The press release and the live webcast can be accessed by going to the
Investor Relations section of the MedImmune website at www.medimmune.com.
Following the webcast, an archived version of the call will be available at
the same address until February 5, 2004.
MedImmune is a leading biotechnology company focused on researching,
developing and commercializing products to prevent or treat infectious
disease, autoimmune disease and cancer. MedImmune actively markets four
products, Synagis(R) (palivizumab), FluMist(TM) (Influenza Virus Vaccine Live,
Intranasal), Ethyol(R) (amifostine) and CytoGam(R) (cytomegalovirus immune
globulin intravenous (human)), and has additional products in clinical
testing. MedImmune employs approximately 1,700 people, is headquartered in
Gaithersburg, Maryland, and has additional operations in Frederick, Maryland,
as well as Pennsylvania, California, the United Kingdom and the Netherlands.
For more information on MedImmune, and for full prescribing information on
MedImmune's products, visit the company's website at www.medimmune.com.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the company's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
/CONTACT: Media: Jamie Lacey, +1-240-632-4035, or Investors: Will
Roberts, +1-301-527-4358 or John Filler, +1-240-632-4086, all of MedImmune,
/Web site: http://www.medimmune.com/
CO: MedImmune, Inc.
IN: HEA MTC BIO
SU: CCA MAV
-- DCTH003 --
1724 01/15/2004 09:00 EST http://www.prnewswire.com